Dupilumab in Young Children With Atopic Dermatitis: Single-Center Real-World Efficacy and Basophil Signal

This uncontrolled prospective cohort of Chinese children aged 6 months to 6 years adds real-world response, family burden, and early-response predictor data to the pivotal randomized evidence for dupilumab in preschool atopic dermatitis (AD).

📅 Journal publication: Jul 22, 2026 · Last updated: Oct 22, 2026

dupilumabinterleukin-4 receptor alpha antagonistmonoclonal antibodyatopic dermatitispediatricinfants and preschool childrenearly super-responderbasophil countallergic rhinitisreal-world prospective cohortcaregiver quality of life Pediatric Pharmacy

Background Information

Dupilumab shows promise for young children with severe eczema.

This study assesses the efficacy and safety of dupilumab for young children with moderate-to-severe atopic dermatitis, offering insights for pediatric treatment strategies. Dupilumab significantly improved skin lesions and pruritus with 87.10% achieving EASI75 by week 16. Predictors of response included lower basophil count and presence of allergic rhinitis. Dupilumab appears safe and effective for children under six with atopic dermatitis. Study limitations include a narrow age range and focus on AD. Dupilumab is effective for pediatric atopic dermatitis and improves related comorbidities.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Ma L, Wei M, Mou W, Xia L, Yu N, Zhao M, Yu P, Jia X, Shang Y

Citation: Ma L, Wei M, Mou W, et al. Dupilumab efficacy in children aged 6 months to younger than 6 years with moderate-to-severe atopic dermatitis and clinical characteristics of early super-responders. BMC pediatrics. 2026;26(1). doi:10.1186/s12887-026-07381-6

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →